SCHEMBL6502046

SCHEMBL6502046

O=CNc1nc(CC(=O)N2CCN(c3ccc(NC(=O)C4=C(c5ccc(C(F)(F)F)cc5)CCCC4)cc3)CC2)cs1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ME2 P23368 1/20 0.41
ME1 P48163 1/20 0.41
ME3 Q16798 1/20 0.41
MAPT P10636 6/20 0.40
LMNA P02545 3/20 0.40
ALDH1A1 P00352 2/20 0.40
CCNC P24863 1/20 0.39
CDK8 P49336 1/20 0.39
HTT P42858 1/20 0.38
F2 P00734 2/20 0.38
F10 P00742 2/20 0.38
MAPKAPK2 P49137 1/20 0.38
POLB P06746 1/20 0.37
CYP2C19 P33261 1/20 0.37
KCNH2 Q12809 1/20 0.37
LCK P06239 1/20 0.36
HCK P08631 1/20 0.36
SRC P12931 1/20 0.36
KDR P35968 1/20 0.36
BTK Q06187 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6490499 0.88 ME2 (0.43) ME2ME1ME3MAPTLMNA
SCHEMBL6500969 0.81 CCNC (0.45) ME2ME1ME3MAPTCCNC
SCHEMBL6500009 0.81 PHGDH (0.49) ME2ME1ME3MAPTCCNC
SCHEMBL6489848 0.77 CCNC (0.44) ME2ME1ME3MAPTLMNA
SCHEMBL6490778 0.74 MAPKAPK2 (0.46) MAPTLMNAALDH1A1MAPKAPK2KCNH2
SCHEMBL6490755 0.73 CA1 (0.51) MAPTLMNAALDH1A1MAPKAPK2POLB
SCHEMBL6496929 0.73 MAPT (0.57) MAPTLMNAALDH1A1HTTMAPKAPK2
SCHEMBL6496056 0.73 MAPKAPK2 (0.66) MAPTLMNAHTTMAPKAPK2KCNH2
SCHEMBL6501481 0.73 CA1 (0.52) MAPTLMNAALDH1A1MAPKAPK2POLB
SCHEMBL6488640 0.72 SRPK1 (0.51) MAPKAPK2KCNH2LCKHCKSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed
EP-1472226-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-11-03 EP disclosed
WO-2003045921-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 ME2 1669/4885ME1 1825/4885ME3 3012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.